Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
ADNOC Gas Targets Up to $4B Profit in 2026 
(4) - EconoTimes)
BRIDGEWATER, N.J., Feb. 21, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to 47 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the February 20, 2018 commencement of their employment, the employees received options to purchase an aggregate 133,010 shares of Insmed common stock at an exercise price of $24.22 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a ten-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company’s lead product candidate is ALIS for adult patients with treatment refractory NTM lung disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Investor Contact:
Blaine Davis
Vice President, Head of Investor Relations
Insmed Incorporated
(908) 947-2841
[email protected]
